In addition to inducing the degradation of IKZF1/3 proteins, lenalidomide induces the degradation of the neoabstract casein kinase 1α (CK1α), resulting in its approval for the treatment of myelodysplastic syndrome (MDS)208. Here, CSNK1A1 is linked to myelodysplastic syndrome.